Delivery Order SPE2DB24D8001-SPE2DB24FKYWF
Award Date
8/7/24
Potential Completion Date
8/8/24
Potential Value
$9.8K
Federal Agency
Defense Logistics Agency
Awardee
Dakota Drug, Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Anoka, MN, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, with ID SPE2DB24D8001|SPE2DB25FKZKH, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $9,440.85, is a delivery order for the pharmaceutical product STELARA 90 MG/ML SYRINGE. It is a firm fixed-price contract with a period of performance extending through March 20, 2025. Dakota Drug, Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA, valued at...
This federal contract award, identified as SPE2DX15D8002|SPE2DX23F2XL4, was issued by the Defense Logistics Agency (DLA) Troop Support Medical division to the prime contractor Dakota Drug, Inc. The $8,963.87 firm fixed-price delivery order is for the procurement of STELARA 90 MG/ML syringes, a pharmaceutical product. The contract has a performance period extending through May 18, 2023 and is not a set-aside award. Dakota Drug, Inc. is a self-certified small disadvantaged business that...
The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order contract to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of STELARA 90 MG/ML SYRINGEML. The contract, valued at $8,085.39, has an ultimate completion date of February 18, 2025. This award is part of the DLA Troop Support Medical's ECAT Generation V Program, a larger Indefinite Delivery Contract (IDC) with Dakota Drug, Inc. valued at $999,999,999.00. The IDC allows the company...
The federal contract award SPE2DB24D8002|SPE2DB24FJMPZ was issued by the Defense Logistics Agency (DLA) to the prime contractor Dakota Drug, Inc., a self-certified small disadvantaged business. The $11,567.65 Firm Fixed Price delivery order is for the pharmaceutical product STELARA 90 MG/ML SYRINGEML, with a performance period ending on July 19, 2024. This contract is not a set-aside award. Dakota Drug, Inc. is an experienced federal contractor, holding a $999,999,999.00 Indefinite Delivery...
This federal contract award, identified as SPE2DX15D8002|SPE2DX24F2VH4, was issued by the Defense Logistics Agency (DLA) to the prime contractor Dakota Drug, Inc., a self-certified small disadvantaged business. The $9,794.51 firm-fixed-price delivery order is for the pharmaceutical product Stelara 90 mg/mL syringe. This contract is not set-aside and is part of Dakota Drug, Inc.'s larger Indefinite Delivery Contract (IDC) SPE2DB24D8001 with the DLA Troop Support Medical's ECAT Generation V...
This federal contract award, identified as SPE2DB24D8001|SPE2DB25FKZLG, was issued by the Defense Logistics Agency (DLA) to the prime contractor Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of STELARA 90 MG/ML SYRINGEML, a pharmaceutical product, to support U.S. Armed Forces medical operations. The contract has a ceiling value of $8,114.16 and a period of performance through March 28, 2025. It is a Firm Fixed Price Delivery Order contract,...
This is a federal contract award from the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $8,445.88, is for the delivery of STELARA 90 MG/ML SYRINGEML, a pharmaceutical product, with a performance period ending on March 18, 2025. The contract is a delivery order issued under Dakota Drug, Inc.'s larger Indefinite Delivery Contract (IDC) with the DLA, identified as SPE2DB24D8001, which has a total potential value of...
This federal contract award, identified as SPE2DB24D8001|SPE2DB25FKZDM, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of STELARA 90 MG/ML SYRINGEML, a pharmaceutical product, with a ceiling value of $9,583.28. This contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) that Dakota Drug, Inc. holds with the DLA, valued at $999,999,999.00. The IDC is part of the DLA...
This federal contract award is for the delivery of STELARA 90 MG/ML SYRINGEML, a pharmaceutical product, to the Defense Logistics Agency (DLA) Troop Support Medical division. The contract, valued at $13,608.63, was awarded to Dakota Drug, Inc., a self-certified small disadvantaged business, on February 23, 2024, with a performance period ending on February 26, 2024. The contract is a delivery order under Dakota Drug, Inc.'s larger Indefinite Delivery Contract (IDC) with the DLA, identified as...
This federal contract award, valued at $14,916.64, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business operating as a for-profit subchapter S corporation. The contract is for the delivery of STELARA 90 MG/ML SYRINGE/ML, a pharmaceutical product, with a completion date of September 5, 2024. Dakota Drug, Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA, identified as SPE2DB24D8001, valued at $999,999,999.00. This...